Patent Validity Issue Underpins High Court Pay-For-Delay Case

Law360, New York (December 10, 2012, 9:44 PM EST) -- The  U.S. Supreme Court has finally decided to examine a long-running antitrust battle between the pharmaceutical industry and the Federal Trade Commission over so-called pay-for-delay settlements, clearing the way for the justices to make some tough calls on the amount of deference courts must give to the settlements — and their underlying patents.

Now that the court has granted certiorari in the FTC's suit over settlements Solvay Pharmaceuticals Inc. inked with several generics makers over testosterone-replacement treatment Androgel, it will have a chance to resolve the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.